Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN) -- Ignore unavailable to you. Want to Upgrade?

To: Jonathan Schonsheck who wrote (4238)	5/25/1999 10:31:00 AM
From: FreedomForAll	Read Replies (1) \| Respond to of 4342

Paracelsian Announces Positive Drug Development Results ITHACA, N.Y., May 25 /PRNewswire/ -- Paracelsian, Inc. (OTC Bulletin Board: PRLN - news) announced today that studies of the activity of Andrographolide in combination with the well known anti-HIV drug AZT have confirmed a significant level of synergy between the two compounds. With the addition of Andrographolide, the study showed, AZT levels could be cut in half while still retaining the same anti-HIV effect. Serquest Inc. of Frederick, Maryland, a Division of the Southern Research Institute carried out the study. ''These results further support Paracelsian's belief in the value of Andrographalide as a pharmaceutical compound that can, in a cost effective way, help people worldwide afflicted with the HIV virus,'' stated Hira L. Gurtoo, President of Paracelsian's Drug Development Division. Paracelsian has a U.S. Patent Pending on the use of Andrographolide for the treatment of HIV and Cancer. The patent is being pursued on an accelerated basis. The company is actively seeking potential partners to develop Andrographolide as a significant addition to AZT in creating an effective but low cost cocktail to treat HIV. Such a combination would be of great value in markets where the cost of more expensive drug cocktails makes them out of reach for most of those suffering from HIV. Andrographolide is an active compound derived from Andrographis Paniculata, one of over 2,700 Traditional Chinese Medicines in Paracelsian's library of TCM's. This library was collected under an ongoing fifteen-year agreement with the Academy of Preventive Medicine, Institute of Nutrition and Food Hygiene in Beijing, China. Under this agreement, Paracelsian's library will be continuously expanded with an ultimate potential of over 7,000 botanicals with a history of beneficial use for an array of health conditions. In addition to its current work with Andrographolide as a potential anti-HIV compound, Paracelsian has an ongoing development program with the Southern Research Institute focusing on the anti-cancer effects of the compound. Paracelsian has recently successfully completed additional experiments in this regard that are expected to be included in additional patent applications in the near future. Paracelsian is a unique biotechnology company whose business centers on the development and application of functional bioassays. These assays are used for Quality Assurance of herbs, botanicals and other dietary supplements, in the development of dietary supplement, OTC and pharmaceutical products, and in monitoring environmental toxins and identifying carcinogens. Notice: This news release may contain forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. SOURCE: Paracelsian, Inc.